|
gptkbp:instance_of
|
gptkb:Antihero
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Brivaracetam
|
|
gptkbp:category
|
gptkb:unknown
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
NCT01396128
NCT01402580
NCT01402581
NCT01402582
NCT01402593
|
|
gptkbp:clinical_use
|
myoclonic seizures
tonic-clonic seizures
partial-onset seizures
|
|
gptkbp:contraindication
|
hypersensitivity to brivaracetam
|
|
gptkbp:dosage_adjustment
|
renal impairment
hepatic impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
oral solution
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
tablets
oral solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Briviact
|
|
gptkbp:ingredients
|
gptkb:brivaracetam
|
|
gptkbp:interacts_with
|
gptkb:beer
oral contraceptives
other antiepileptic drugs
|
|
gptkbp:lifespan
|
approximately 8 to 9 hours
|
|
gptkbp:manufacturer
|
gptkb:UCB_Pharma
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
SV2 A ligand
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
blister pack
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:provides_guidance_on
|
gptkb:Epilepsy_Foundation
gptkb:American_Academy_of_Neurology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
dizziness
fatigue
nausea
aggression
irritability
drowsiness
suicidal thoughts
mood changes
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:treatment
|
monotherapy
adjunctive therapy
|
|
gptkbp:used_for
|
treatment of epilepsy
|
|
gptkbp:bfsParent
|
gptkb:UCB_S._A.
|
|
gptkbp:bfsLayer
|
6
|